BioSpace News Archive

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today announced that all subjects participating in its 755-101-HV Phase 1 clinical trial have completed treatment and clinical evaluation.

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to deliver oxygen to the areas where it is needed most, today announced that it has begun a cooperative research effort with University of Virginia Health (UVA) and the Integrated Translational Research Institute of Virginia (

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and for other public health threats for civilian, government and military use, today announced that the Biomedical Advanced Research and Development Authority (BARDA) has initiated funding to support the onshoring of Paratek manufacturing activities for NUZYRA.

Enables Providers to Prescribe PainShield to Help Individuals Manage Pain at Home, Avoiding Unnecessary Doctor Visits and Hospitalization During COVID-Related Stay-At-Home Proclamations

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it received a Notice of Award of $730,722 in a grant supporting the Ovaprene® postcoital test (PCT) clinical study research from the Eunice Kennedy Shriver National Institute of Child Health & Human Development, a division of the National Institutes of Health (NIH)

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology, today provided an update on its business strategy and financial position in light of the current COVID-19 situation.

Shimadzu Medical Systems USA, completes the integration of Core Medical Imaging Inc., a subsidiary of SMS into the company.

IceCure Medical Ltd (TASE: ICCM), a developer and marketer of minimally invasive cryoablation therapies for women’s health and Interventional oncology markets, announced today that it has received its largest purchase order (PO) for ProSense™ system from Bumrungrad International Hospital, a leading hospital based in Thailand.

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the achievement of key milestones reflecting portfolio-wide progress against the company’s 2020 goals

Seneca Biopharma, Inc. (Nasdaq: SNCA), a clinical-stage biopharmaceutical company developing novel treatments for diseases of high unmet medical need, announced today the appointment of Matthew W. Kalnik, Ph.D. as President and Chief Operating Officer (COO) and Dane R. Saglio as Chief Financial Officer (CFO).